

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Effects of ketamine treatment on suicidal ideation: a study of patients' accounts

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029108
Article Type:	Research
Date Submitted by the Author:	19-Feb-2019
Complete List of Authors:	Lascelles, Karen; Oxford Health NHS Foundation Trust; Centre for Suicide Research, Department of Psychiatry, University of Oxford Marzano, Lisa; Middlesex University, Psychology Brand, Fiona; Centre for Suicide Research, University Department of Psychiatry, Oxford; Oxford Health NHS Foundation Trust Trueman, Hayley; Oxford Health NHS Foundation Trust McShane, Rupert; University of Oxford, Cochrane Dementia and Cognitive Improvement Group (CDCIG), Nuffield Department Medicine; Oxford Health NHS Foundation Trust Hawton, Keith; Centre for Suicide Research, Oxford University, Psychiatry
Keywords:	ketamine, treatment-resistant depression, mechanisms, self-harm, suicidal ideation

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9 **Effects of ketamine treatment on suicidal ideation: a study of patients' accounts**
10
11
12
13
14
15
16

17 Karen Lascelles, Lisa Marzano, Fiona Brand, Hayley Trueman, Rupert McShane,
18
19 Keith Hawton
20
21
22
23

24 Corresponding Author:
25
26

27 Keith Hawton keith.hawton@psych.ox.ac.uk
28 Professor Keith Hawton, FMedSci DSc FRCPsych,
29 Director, Centre for Suicide Research,
30 University Department of Psychiatry,
31 and Consultant Psychiatrist,
32 Oxford Health NHS Foundation Trust,
33 Warneford Hospital,
34 Oxford, OX3 7JX. UK
35 Tel: 00 44 (0)1865 902285
36
37
38
39

40 Author:
41

42 Karen Lascelles, Oxford Health NHS Foundation Trust; Centre for Suicide Research,
43 Department of Psychiatry, University of Oxford, Oxford UK
44

45 Co-authors:
46

47 Dr Lisa Marzano, Middlesex University, London UK
48 Fiona Brand, Oxford Health NHS Foundation Trust; Centre for Suicide Research, Department
49 of Psychiatry, University of Oxford, Oxford UK
50 Hayley Trueman, Oxford health NHS Foundation Trust, Oxford UK
51 Dr Rupert McShane, Oxford health NHS Foundation Trust, Oxford UK
52 Professor Keith Hawton, Oxford health NHS Foundation Trust; Centre for Suicide Research,
53 Department of Psychiatry, University of Oxford, Oxford UK
54
55

56 **Key words**
57

58 Ketamine, suicidal ideation, treatment-resistant depression, mechanisms, self-harm
59

60 Word count: 4501

ABSTRACT

Objective: It is recognised that ketamine treatment can reduce suicidal ideation (SI) in people with depression, at least in the short term. However, information is lacking on patients' perspectives on such effects. The aim of this study was to investigate patients' reports of the impact of treatment with ketamine on their SI, the duration of effects and possible mechanisms.

Design and setting: This qualitative study consisted of semi-structured interviews with patients with treatment-resistant depression, including SI, all but one of whom who had received treatment with ketamine within the last year. Interview data were analysed thematically.

Participants: Fourteen patients (8 females, 6 males, aged 24-64 years) who received treatment with ketamine in the preceding year for treatment-resistant depression, who also had SI at the initiation of treatment. Eight had a history of self-harm.

Results: SI reduced following ketamine treatment in 12 out of 14 participants for periods of a few hours following a single treatment to up to three years with ongoing treatment. However, reduction of SI was variable in terms of extent and duration, and re-emergence of suicidal thoughts often occurred when treatment ceased. Participants' accounts indicated that reduced SI was associated with improved mood and reduced anxiety, as were clarity of thought, focus and concentration, and ability to function. Participants reported experiencing some or all of these effects in various orders of occurrence.

Conclusion: Generally, ketamine treatment was experienced as effective in reducing suicidal ideation, although duration of effects varied considerably. There is a need to identify patients with suicidal ideas who are likely to respond to ketamine, and also interventions that may enhance its anti-suicidal effects. The benefits experienced by participants in this study may provide opportunities for engagement in psychological interventions to help manage suicidal ideation and associated intrusive thoughts between treatments.

Strengths and limitations of this study

- This is one of the first studies of the impact of ketamine on suicidal ideation based on qualitative investigation of patients' experiences.

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- Participants comprised a heterogeneous group in terms of gender, age, and number and routes of treatments with ketamine.
- The study is limited by the relatively small number of participants.
- Suicidal ideation was identified through a single item on a depression scale.
- Some patients declined participation.

For peer review only

INTRODUCTION

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Suicide is a major public health problem globally (1). It often occurs in the context of depression (2,3). While both pharmacological and psychological treatments can reduce depression and suicidality (4), there is an important group of individuals who have treatment-resistant depression in whom suicidal thinking is common and who have increased risk of a suicidal act (5). Ketamine, which is an N-Methyl-D-aspartate receptor antagonist, has received increasing attention as a rapid-acting antidepressant, with studies suggesting that a single low dose infusion has a beneficial although transitory effect for patients with depression, including treatment-resistant unipolar and bipolar depression (6–8). There is accumulating evidence from clinical and randomised controlled trials that ketamine can reduce suicidal ideation (SI), at least in the short term (9–11). However, there is uncertainty as to the mechanisms which might underlie this effect (12). Reduction in SI mediated by improvement in overall depressive symptoms may be one factor (13), but it also seems that improvements can occur independently from changes in mood (14–16).

As far as we are aware, research to date has not examined patient views regarding the impact of ketamine treatment on SI or sought to understand how patients think that ketamine has reduced their SI. The aim of this qualitative study was to explore patient perspectives on the impact of ketamine treatment on SI in the context of treatment-resistant depression, including perceived benefits and how these might occur.

METHOD

Participants

Inclusion criteria consisted of a diagnosis of unipolar or bipolar treatment resistant depression, age 18 years or over, English speaking, SI at commencement of treatment and ketamine treatment within the past year. SI was assessed by a score of 1 or above on the suicidal ideation question of the Beck Depression Inventory (BDI) (17). Exclusion criteria were a lack of mental capacity, significant impairment of intellectual functioning and lack of fluency in spoken English.

Recruitment

All participants were recruited from a ketamine clinic in Oxford which provides treatment to individuals from across the UK. Standard treatment at this clinic is an initial three intravenous ketamine treatments (infusions) [0.5mg/kg] followed by oral ketamine or a combination of oral and intravenous treatments as needed.

Forty eligible participants were approached by the ketamine clinic staff (HT and RM) by email or in person at the clinic. Participant information sheets were provided and interested individuals were referred to the researcher (KL), who then provided further information before undergoing the informed consent process (see online appendix for further information in the completed Consolidated Criteria for Reporting Qualitative Research Checklist). Patients approached included both those who had responded positively to ketamine treatment and patients who had not experienced any tangible benefit or who had stopped treatment due to side-effects.

Data collection

Data collection was through one-to-one semi-structured interviews carried out by the researcher (KL) at the hospital site where the ketamine clinic is based. All interviews were carried out face-to face, although two longer interviews were carried out in two parts, with the second parts by phone or skype. Topics included history of depression and suicidality, the circumstances under which participants started ketamine treatment, their experiences of treatment and perspectives on impact of ketamine on mood and SI. In addition, participants were asked to complete the BDI before the interview commenced (only the pre-treatment score was used to determine eligibility). They also completed benefits and side-effects checklists during the interview to gather structured information about frequency and duration of effects.

The length of interviews ranged from one to two and a half hours. All interviews were tape recorded. Participants were advised that they could withdraw from the study at any time and provided with information about sources of support in case they became distressed following the interview.

Analysis

Interview data were transcribed verbatim and participants were given the opportunity to review their anonymised transcripts. Six participants took up this opportunity but none suggested changes. Thematic analysis was carried out to report participants' experiences, meanings and realities using an inductive and semantic approach, following the six stages of analysis recommended by Braun and Clarke (2006) (18): 1. Becoming familiar with the data; 2. Generating initial codes; 3. Searching for themes; 4. Reviewing themes; 5. Defining and

1
2
3 naming themes; 6. Write-up. Final identification of themes was based on consensus
4
5 discussion between two researchers (KL and FB), and was supported by NVIVO software
6
7 (version 11 QSR 2008). Main themes and subthemes were first identified in relation to
8
9 separate participants, and then across the whole sample. The qualitative analysis was
10
11 supervised by LM.
12
13
14
15
16
17

18 **Patient and public involvement**

19
20 A former patient of the ketamine clinic was involved in reviewing and providing feedback on
21
22 the interview schedule and participant information literature prior to submission to the
23
24 Local Research Ethics Committee.
25
26
27
28
29
30

31 **Ethical approval**

32
33
34 The study was approved by the South Central Oxford A Research Ethics Committee and the
35
36 Health Research Authority (Reference No. 17/SC/0106).
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Participants

In total, 40 current and past patients were approached (21 females and 19 males). 18 individuals expressed initial interest in the study and 14 (35%, 8 females and 6 males) went on to participate. Of the 4/18 patients who did not go on to take part, three didn't respond to invitations to meet with the researcher and one withdrew before the informed consent process. One of the final 14 participants had stopped treatment 16 months prior to commencement of the study (22 months prior to interview) due to non-response but was included in the sample to ensure a range of perspectives. Participants were predominantly White British (13/14), with one classed as White Other. Ages ranged from 24-64 years, with a median age of 41 years. Most (11) participants lived with others (spouses, partners, parents, house share, student accommodation), with three living alone. Six participants were registered as sick or disabled at the time of their interviews.

All 14 participants met criteria for treatment-resistant depression (Anderson, 2018). Two had a primary diagnosis of bipolar affective disorder type 1, two a diagnosis of emotionally unstable personality disorder, and the remaining 10 a primary diagnosis of depression. BDI scores for the suicidal ideation question at the start of ketamine treatment and at interview are shown in Table 1.

(Table 1 about here)

Ketamine treatment

1
2
3 Ten participants were engaged in ongoing ketamine treatment at the time of interview. Of
4
5 the remaining four, one had received ketamine a month prior to interview, two nine months
6
7 before and one 22 months prior to interview. Reasons for cessation of treatment were non-
8
9 response (N=1), treatment becoming ineffective over time (N=1), severe side-effects (N=1),
10
11 and a lack of supply of oral ketamine (N=1).
12
13
14
15
16
17

18 There was considerable variation in the length of time participants were involved in
19
20 treatment. Two individuals received between one and three infusions over a few weeks, five
21
22 had between 6 and 88 infusions and up to 199 oral doses over a year or more (19 months –
23
24 6 years, three consistently and two periodically). The length of treatment and number of
25
26 doses for the remaining seven was somewhere between these points (3-6 infusions and up
27
28 to 46 oral doses over 4-9 months).
29
30
31
32
33
34

35 **Impact of ketamine on suicidal ideation**

36
37 Twelve participants reported a reduction in SI at some stage following ketamine treatment.
38
39 The onset and duration of this effect varied; onset ranged from immediate to a day or more
40
41 after treatment, and duration from less than 24 hours to three years with ongoing
42
43 treatment (Table 2). One patient who reported a reduction in suicidal ideation had
44
45 treatment stopped after one infusion due to adverse side-effects (see below). Of the two
46
47 participants who did not report a reduction in SI, one did not experience any noticeable
48
49 benefit from ketamine at all apart from a mild and transient improvement in mood; the
50
51 other experienced improved energy levels and cognitive function but only rarely any
52
53 improvement in mood.
54
55
56
57
58
59
60

1
2
3 Four participants experienced sustained elimination of suicidal ideation on both intravenous
4
5 and oral ketamine.
6
7

8
9 *“And the strongest thing that’s come out of the ketamine is that it doesn’t*
10
11 *matter how down I’ve got, after maybe the first one, maybe two, the idea of*
12
13 *suicide is not there” (P3).*
14
15

16
17
18
19
20 (Table 2 about here)
21
22
23
24
25

26 Two of these four participants (three of whom were receiving ketamine at the time of
27
28 interview) noticed a return of SI during periods they were without treatment (between
29
30 intravenous and oral treatment, or when they ran out of oral treatment), although stated
31
32 that the ideation was less intense.
33
34

35
36 *“[SI returned] Only when I’ve been off it for two months.... but not quite as bad as*
37
38 *I’ve experienced it before..... the fact that the thought had flashed into my mind*
39
40 *at all was like, ah and now it’s time to get in contact.” (P6)*
41
42
43
44
45

46
47 Three participants experienced an elimination of SI following intravenous treatment, which
48
49 lasted from 6 hours to 9 months (6 hours; 6-8 days; 3-9 months). One of these participants
50
51 had only ever received intravenous ketamine; the others had received both intravenous and
52
53 oral treatment but experienced elimination of SI only with intravenous administration,
54
55 although they reported a reduced intensity of suicidal ideation on oral ketamine.
56
57
58
59
60

1
2
3 *"I thought if it doesn't work, on the way back, because we were staying in a hotel*
4 *on the way back, and I was going to kill myself there.....I actually went and*
5 *had dinner with my dad in the hotel room on the way back, which I've never done*
6 *before. Usually I wouldn't be up to doing that mood wise. And I was able to eat*
7 *and enjoy the food..... [The oral] never had the impact of reducing the suicidal*
8 *thoughts to the extent that the infusion did..... on the infusion they*
9 *disappeared." (P8)*
10
11
12
13
14
15
16
17
18
19
20
21
22
23

24 A further participant had only one full intravenous treatment before stopping due to side
25 effects (exacerbated hallucinations and intrusive unpleasant thoughts), but reported a
26 period of a few hours of relief from persistent SI on the third day after the first treatment,
27 which they attributed to the ketamine.
28
29
30
31
32
33

34 A reduction in SI was reported by six participants (including two of the three discussed
35 above who experienced elimination of thoughts of suicide on intravenous ketamine but not
36 oral), which manifested as a reduction in intensity rather than frequency, with content
37 unchanged.
38
39
40
41
42
43

44
45 *"The intensity of the thought is definitely reduced.....I can cope with the*
46 *frequency, lots of them at a small level, I'm so used to them that it doesn't bother*
47 *me. But if I get lots at a high intensity, this is when things start to break down.*
48 *So reducing the intensity is the first step for me." (P2)*
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The intravenous ketamine treatment was experienced as considerably stronger and, for
4
5 most participants, more effective than oral treatment in reducing SI, although eight of the
6
7
8 nine individuals who had oral treatment did report some benefit from it.
9

10
11 *“The oral dose, I suppose is stopping me from doing a suicide attempt even*
12
13 *though I still have those suicidal feelingsit lessened the intensity of them so*
14
15 *I would think I’ll hold on for a bit longer and see what, thinking more of other*
16
17 *people.” (P8)*
18
19
20
21
22
23
24

25 Notwithstanding the greater effect of intravenous ketamine, one participant preferred the
26
27 regime of having the more regular, albeit lower, doses permitted by taking ketamine orally.
28
29 Another favoured oral treatment because, although it did not eradicate suicidal ideation as
30
31 the intravenous treatment did, there was not such a significant drop in mood when the
32
33 effects wore off and improved functionality was more sustained.
34
35
36
37
38
39
40

41 **Dissociative and euphoric effects**

42
43

44 Dissociative effects during ketamine treatment were experienced some or all of the time by
45
46 the 12 participants who reported a positive impact on SI (and also by the two participants
47
48 who did not experience reduced SI). These effects were more common and stronger with
49
50 intravenous treatment and one participant reported no dissociative effects at all with oral
51
52 treatment. To describe the difference one participant likened the oral ketamine to a
53
54 drinking a glass of wine and the intravenous to consuming a bottle of vodka.
55
56
57
58
59
60

1
2
3 Participants were not asked specifically if they thought the reduction in their suicidal
4
5 ideation was linked to the dissociative effects they experienced. However, when asked if
6
7 they had discovered ways of maximising the overall benefit of ketamine, five participants
8
9 said they would take oral ketamine on an empty stomach to achieve a stronger sense of
10
11 dissociation and derive more benefit, suggesting they believed there was such a link,
12
13 although two participants noted that in practice this was not always the case.
14
15
16

17
18 *“Sometimes I won’t get as much of a kick from taking it, almost not notice
19
20 and I’m like did I get any? and then the next week will be fine. Sometimes I’d
21
22 get a really powerful thing and the next week felt down, so there was definitely
23
24 some stuff going on there that was beyond my ability to make sense of.” (P6)
25
26
27
28
29
30
31*

32 One participant reported getting the giggles and feeling like a ‘happy drunk’ during
33
34 intravenous ketamine treatment and two others described clear euphoric effects.
35
36

37
38 *“It was like a weight had been lifted off my shoulders. It was like I’d let go of a
39
40 big weight, like a heavy weight had shifted from me. It was absolutely amazing.”
41
42 (P1)
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60*

These three participants all experienced an eradication of SI following ketamine infusions.
For two this was transitory and for one it was longer lasting (for some months following a
course of four infusions).

Perceived mechanisms contributing to reduced suicidal ideation

1
2
3 Participants rated the frequency with which they experienced benefits following ketamine
4 treatment using a structured checklist (Table 3). Of the 12 participants whose SI was
5
6 reduced by ketamine, five reported that they always experienced a reduction in SI following
7
8 treatment, although improved mood, reduced anxiety and increased energy were
9
10 experienced less regularly. This suggests that in some cases SI was reduced independently
11
12 of mood and anxiety.
13
14
15
16

17
18 *"I think it's separate [from mood]. Because there's still days where I feel very low*
19
20 *and normally the suicide thing would be at the back of my head or be there, but*
21
22 *it, without any thought process, it's gone, and I can't reason that one."* (P3)
23
24
25
26
27
28
29

30 Table 3 about here
31
32
33
34
35

36 Themes derived from participants' narratives reflect the checklist findings and indicate that
37
38 whilst improved mood and reduced anxiety were both associated with a reduction in SI,
39
40 clarity of thought, improved focus and concentration, and improved ability to function were
41
42 additional factors involved the alleviation of SI (Figure 1; Table 4).
43
44
45
46
47
48
49

50 (Figure 1 about here)
51
52
53
54
55

56 Participants reported similar perceptions of the mechanisms involved in reduction of
57
58 suicidal ideation but some differences in experiences of order of occurrence. Most (N=8)
59
60

1
2
3 perceived that an improvement in mood resulted in reduced suicidal ideation, but for others
4
5 the improvement in mood was itself a result of improved clarity of thought and the
6
7 associated ability to focus.
8
9

10
11 *"I think it may be more ways, not necessarily my mood, maybe that I could have a*
12
13 *gap in thinking without the thoughts coming in. So I could distract and therefore*
14
15 *look at other things that could help my mood, which then I suppose reduces the*
16
17 *suicidality, because when the mood goes really low I can't concentrate on*
18
19 *anything or think about other things. So basically, the ketamine helps to give you*
20
21 *a different perspective at looking outwards and being interested in different*
22
23 *things so I'm not being wound in constant thoughts."* (P8)
24
25
26
27
28
29
30
31

32 Improved clarity of thought was experienced by some participants (N=7) as a reduction in
33
34 intrusive thoughts or depressive ruminations. Such thoughts were negative and frequently
35
36 suicidal in nature and described as *'constant thoughts'*, *'tornado of thoughts'*, *'rapid fire*
37
38 *thoughts'*, *'head swimming'* and *'ruminations'*.
39
40
41

42 *"The day after [ketamine treatment] I maybe have more clarity of thought. I*
43
44 *think instead of maybe being so locked into the pattern of kind of cyclical thinking*
45
46 *and rumination, I think it does maybe break that up a bit and maybe make you a*
47
48 *bit more open to possibilities"* (P4)
49
50
51
52
53
54
55

56 Other participants (N=3) described a process of making sense of thoughts and reaching new
57
58 understandings or gaining new perspectives. Two of these participants used the same
59
60

1
2
3 metaphor (“it’s like rinsing my brain out”, “it’s like having your brain jet washed”) to
4
5 describe this experience. The remaining two participants experienced a relief from slowed
6
7 thinking and used the same descriptors for their state before treatment with ketamine
8
9 (“nothingness”, “this blank nothing”) and the metaphor of “the fog lifting” to describe how
10
11 they felt ketamine enabled clarity of thought.
12
13
14

15
16 Ketamine’s positive effect on anxiety was noticed by most participants who experienced a
17
18 reduction in suicidal ideation (N=11/12). Some put this down to the reduction in intrusive
19
20 negative and suicidal thoughts whereas others described a general reduction in anxiety that
21
22 was associated with improved ability to focus, which in turn prevented intrusive thoughts.
23
24

25
26 *“It’s linked with the focus right, so if you’re focused on your task or what’s in*
27
28 *front of you at the time, there’s no place for neurotic and other thoughts to kick*
29
30 *in and actually then lead you to suicidal thoughts” (P12)*
31
32

33
34
35
36
37 Clarity of thought and the ability to focus along with increased energy levels were linked to
38
39 improved functionality in relation to activities of daily living and socialisation.
40
41

42
43 *“By the thoughts being slowed down you automatically gain more control because you can isolate*
44
45 *them.....everything seems more manageable at a slower pace..... the mood is able to go up and the*
46
47 *suicidal thinking comes down.... It means I can do things. I can get out of bed. I can take my kids to*
48
49 *school. I can have a shower.....” (P2)*
50
51

52
53 (Table 4 about here)
54
55

56 57 58 59 **Side-effects** 60

1
2
3 All participants experienced some side-effects, including the effects during ketamine
4
5 administration, ranging from rarely to always (the most frequently reported of which were
6
7 feeling strange or unreal (N=14), abnormal sensations e.g., seeing or hearing unusual things
8
9 (N=11), tiredness (N=11), blurred vision (N=8) and headaches (N=7). One participant
10
11 reported severe side-effects resulting in cessation of treatment (see above). For the rest of
12
13 the participants (N=13) however, side-effects were not considered major and six explicitly
14
15 stated that the side effects they experienced from ketamine were much less than those they
16
17 had experienced with conventional antidepressants. No participants described an
18
19 association between side effects and impact of ketamine on suicidal ideation.
20
21
22
23
24
25
26
27
28

29 **Self-harm**

30
31
32 Two of the 14 study participants had self-harmed whilst undergoing ketamine treatment.
33
34 One of these reported an overall reduction in intensity of suicidal ideation. A third
35
36 participant, who had ketamine periodically over some years, had episodes of self-harm
37
38 when in a mental health crisis, while not receiving ketamine, which led to further courses of
39
40 ketamine treatment. A fourth participant had self-harmed since cessation of ketamine
41
42 treatment (due to side effects). All of these participants had a history of self-harm prior to
43
44 commencement of ketamine treatment.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

There is growing interest in the potential use of ketamine for acute treatment of suicidal thinking and behaviour. This is partly because there is a lack of treatments with rapid effects on SI. In this study we have examined patient's accounts of the impact of ketamine on their suicidal thinking.

Impact of ketamine on SI

Treatment with ketamine was reported as reducing SI in 12 out of 14 participants. However, the intensity and duration of effects on suicidal ideation varied greatly. In most clinical trials which have shown an impact of a single treatment with ketamine on suicidal ideation, this effect has not usually persisted beyond 72 hours (11,19,20), although has had longer effects in some patients. In the present study, some participants who reported benefits in terms of reduced SI identified a relatively long duration of effect. Grunebaum et al (2017) found an effect on suicidal ideation up to 6 weeks following a single infusion of ketamine (10). Also, in our study all but one individual had received multiple ketamine treatments. Some of these reported that beneficial effects on suicidal ideation persisted with continuation of treatment, but that this effect was lost if treatment was discontinued.

Differences between individual experiences of impact of ketamine on suicidality have been noted by other authors, such as Ballard et al (2018) who found that those least likely to have reduced SI following ketamine were those with the most severe SI and a history of self-injury (16). Of the eight participants in our study who scored 2 or above in the BDI suicidal ideation question, six had a history of self-harm. Five of these reported a beneficial impact on SI; one complete elimination, two elimination with ketamine infusion and reduction with

1
2
3 oral treatment, and two an overall reduction. These findings indicate that most participants
4
5 who had stronger SI and a history of self-harm experienced a reduction in SI following
6
7 ketamine treatment. The rest of the participants (N=6) had less severe SI and fewer (N=2)
8
9 had a history of self-harm. However, responses of this group were similar to the group with
10
11 higher SI; one reported no response; two reduced SI and three elimination of SI.
12
13
14
15
16
17

18 One possibility for optimising improvement in thought processes and functionality
19
20 experienced following ketamine treatment, and hence longer-term benefits for both
21
22 depression and suicidal ideation, could be additional use of intensive psychological therapy.
23
24 Some participants in this study spontaneously mentioned the need for psychological
25
26 treatment and the fact that ketamine made them feel more amenable to therapy or more
27
28 able to utilise skills learnt in previous therapy. Repeated treatment with ketamine, as was
29
30 the case for several participants in this study, is another approach.
31
32
33
34
35
36
37

38 **Potential mechanisms of impact of ketamine on SI**

39
40 Participants' accounts indicated that they regarded the beneficial effects of ketamine on SI
41
42 to be partly related to improvements in depression and anxiety. However, some also related
43
44 the impact on suicidal ideation to improved clarity of thinking and functionality. This is in
45
46 keeping with findings from other studies that improvements in SI following a single
47
48 treatment with ketamine can occur partly independently of improvements in mood, with
49
50 improvement in depression explaining about 50% of the improvement in suicidal ideation
51
52 (10,11). Grunebaum et al (2017) found that reduced SI largely continued up to six weeks
53
54 post infusion and explained that this is likely to be partly due to concomitant treatment with
55
56
57
58
59
60

1
2
3 other psychotropic medication, although the participants were not necessarily suffering
4
5 from treatment-resistant depression (10).
6
7
8
9

10 11 **Research implications**

12
13
14 The variety of responses found in this study and other investigations indicate that measures
15
16 of impact should be monitored frequently in trials assessing the impact of ketamine on
17
18 suicidal ideation and behaviour. Further work is needed to try to identify likely responders.
19
20 This will be particularly important should ketamine be used for management of SI in
21
22 emergency situations. Our findings, and those of others (10,16), suggest that there should
23
24 be more focus on investigating the mechanisms involved in beneficial effects of ketamine on
25
26 SI. We would encourage deployment of mixed-methods studies, including nested qualitative
27
28 studies within RCTs, for this purpose and for obtaining a more nuanced appraisal of the
29
30 effects of ketamine than may be possible by only using scales to assess impact.
31
32
33
34
35
36
37
38
39

40 41 **Strengths and limitations**

42 We are unaware of previous qualitative studies of the experiences of depressed patients
43
44 with suicidal ideas receiving treatment with ketamine. The approach we have used
45
46 encourages a real-world appraisal of the impact of ketamine and allows highlighting of
47
48 individual patients' experiences. However, there are limitations, especially in terms of the
49
50 small sample size and the potential lack of generalisability associated with the qualitative
51
52 methodology. In addition, participants who responded to invitations to participate were
53
54 self-selected and there may be some bias in terms of those agreeing to participate perhaps
55
56 having experienced a more positive impact on their SI than those who declined. The
57
58
59
60

1
2
3 inclusion criteria included a positive score on a single item on a mood scale, the Beck
4
5 Depression Scale. Differences in response to ketamine in terms of suicidal ideation have
6
7 been found when different measures of suicidal ideation have been used (11). The
8
9 participants all attended a single clinic, which may also influence the generalisability of the
10
11 findings. Furthermore, the interviews were conducted retrospectively and at varying times
12
13 following initiation of treatment, with some participants still receiving ketamine and others
14
15 having ceased treatment.
16
17
18
19
20
21
22

23 **Conclusions**

24
25 This study of patients' experiences of treatment with ketamine has indicated variable
26
27 responses in terms of changes in suicidal ideation, both in intensity and duration of benefits.
28
29 The patients' perceptions of mechanisms involved in a reduction of suicidal ideation suggest
30
31 that improvements in depression and anxiety are just part of the effect, with improved
32
33 clarity of thinking and functionality also being important. Further studies of patients'
34
35 experiences are warranted, especially in terms of understanding variability of effects of
36
37 ketamine on suicidality, including actual suicidal behaviour, and how benefits of the
38
39 medication might interact with activities of daily living and other treatments, including
40
41 possible psychological therapy. Such work should add to knowledge about the suitability of
42
43 use of ketamine to treat suicidality, especially in potential emergency situations.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. World Health Organization (WHO). Preventing suicide: A global imperative. World Health Organization. 2014.
2. Cavanagh JTO, Carson AJ, Sharpe M, Lawrie SM. Psychological autopsy studies of suicide: a systematic review. *Psychol Med*. 2003;33:395–405.
3. Brezo J, Paris J, Turecki G. Personality traits as correlates of suicidal ideation, suicide attempts, and suicide completions: a systematic review. *Acta Psychiatr Scand*. 2006;113:180–206.
4. Zalsman G, Hawton K, Wasserman D, van Heeringen K, Arensman E, Sarchiapone M, et al. Suicide prevention strategies revisited: 10-year systematic review. *The Lancet Psychiatry*. 2016;3:646–59.
5. Anderson IM. We all know what we mean by treatment-resistant depression – Don't we? *Br J Psychiatry*. 2018;212:259–61.
6. Caddy C, BH A, TL M, JM R, TA F, McShane R, et al. Ketamine and other glutamate receptor modulators for depression in adults. *Cochrane Database Syst Rev*. 2015;9:CD011612.
7. McCloud TL, Caddy C, Jochim J, Rendell JM, Diamond PR, Shuttleworth C, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. *Cochrane Database Syst Rev*. 2015;9:CD011611.
8. Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK. Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. *Aust N Z J Psychiatry*. 2013;47:710–27.

- 1
2
3 9. Bartoli F, Riboldi I, Crocamo C, Di Brita C, Clerici M, Carrà G. Ketamine as a rapid-
4 acting agent for suicidal ideation: A meta-analysis. *Neurosci Biobehav Rev*.
5
6 2017;77:232–6.
7
8
9
- 10
11 10. Grunebaum MF, Galfalvy HC, Choo TH, Keilp JG, Moitra VK, Parris MS, et al. Ketamine
12 for rapid reduction of suicidal thoughts in major depression: A midazolam-controlled
13 randomized clinical trial. *Am J Psychiatry*. 2017;175:327–33.
14
15
16
17
18
- 19
20 11. Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al. The
21 effect of a single dose of intravenous ketamine on suicidal ideation: A systematic
22 review and individual participant data meta-analysis. *Am J Psychiatry*. 2018;175:150–
23
24
25
26
27 8.
28
- 29
30 12. Price RB, Mathew SJ. Does ketamine have anti-suicidal properties? Current status and
31 future directions. *CNS Drugs*. 2015;29:181–8.
32
33
34
- 35
36 13. Price RB, Iosifescu D V., Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, et al. Effects of
37 ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in
38 treatment-resistant depression. *Depress Anxiety*. 2014;31:335–43.
39
40
41
42
- 43
44 14. Phillips JL, Norris S, Talbot J, Owoeye O, Blier P. Direct effect of ketamine on suicidal
45 ideation independent of its effects on depressive symptoms. *Eur*
46
47
48
49 *Neuropsychopharmacol*. 2016;26:S472.
50
- 51
52 15. Ballard ED, Wills K, Lally N, Richards EM, Luckenbaugh DA, Walls T, et al. Anhedonia as
53 a clinical correlate of suicidal thoughts in clinical ketamine trials. *J Affect Disord*.
54
55
56
57 2017;218:195–200.
58
- 59
60 16. Ballard ED, Yarrington JS, Farmer CA, Richards E, Machado-Vieira R, Kadriu B, et al.

- 1
2
3 Characterizing the course of suicidal ideation response to ketamine. *J Affect Disord.*
4
5 2018;241:86–93.
6
7
8
9 17. Beck AT, Schuyler D, Herman I, Resnik HLP, Lettieri DJ. Development of Suicidal Intent
10
11 Scales. In: *The Prediction of Suicide*. Philadelphia, PA: Charles Press; 1974. p. 45–56.
12
13
14 18. Braun V, Clarke V. Using Thematic Analysis in Psychology. *Qual Res Psychol.*
15
16 2006;3:77–101.
17
18
19
20 19. Xu Y, Hackett M, Carter G, Loo C, Gálvez V, Glozier N, et al. Effects of Low-Dose and
21
22 Very Low-Dose Ketamine among Patients with Major Depression: A Systematic
23
24 Review and Meta-Analysis. *Int J Neuropsychopharmacol.* 2016;19:pyv124.
25
26
27
28 20. Murrough JW, Iosifescu D V., Chang LC, Al Jurdi RK, Green CE, Perez AM, et al.
29
30 Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-
31
32 site randomized controlled trial. *Am J Psychiatry.* 2013;170:1134–42.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Characteristics of the participants (N=14)

Characteristics	N=14
Gender (male/female)	6/8
Age (years)	24-64; median 41
Past self-harm	8
Family history of self-harm or suicide	4
BDI suicidal ideation score:	
At commencement of treatment	1 N=7
	2 N=5
	3 N=2
At interview	0 N=6
	1 N=4
	2 N=3
	3 N=1

Table 2: Impact of ketamine on suicidal ideation (SI) in those patients who experienced benefit (N=12)

Onset of reduced SI		N=12
Immediate/during treatment		2
Within an hour of treatment		5
A few hours after treatment		2
A day or more after treatment		3
Duration of reduced SI		
0-24 hours		2
Several days		4 (3-6 days)
A week or more		0
A month or more		1
Ongoing		5

Table 3: Participants' responses regarding specific impacts of ketamine

		Participants with reduced suicidal ideation (N=12)	Participants with no reduction in suicidal ideation (N=2)
Ketamine reduced suicidal ideation	Always	5*	
	Often	5	
	Sometimes	2	
	Never		2
Ketamine improved mood	Always	3*	1
	Often	7	
	Sometimes	2	1
Ketamine reduced anxiety	Always	2*	
	Often	8	1
	Sometimes	1	
	Rarely		1
	Never	1	
Ketamine increased energy levels	Always	2	
	Often	5	1
	Sometimes	5*	
	Rarely		1

*One of these participants had only 1 full intravenous treatment due to severe side-effects

Table 4: Key themes, subthemes and perceived impact of subthemes

Main Themes	Subthemes	Perceived Subthemes
1. Clarity of thought	Reduced intrusive thoughts Relief from slowed thoughts Reaching new understandings	Getting a break
2. Focus and concentration	Able to make decisions Motivation and energy	Choosing not to act on SI Able to let go Seeing other options
3. Ability to function	Activities of daily living Socialisation	Doing normal stuff Improved connection with others

Author Affiliations:

¹ Oxford Health NHS Foundation Trust

² Centre for Suicide Research, Department of Psychiatry, University of Oxford

³ Faculty of Science and Technology, Middlesex University

Acknowledgements

The authors thank Suzanne Pullin and Charlie Pullin for their funding, Chris Dammers for his contribution to the research design and the staff of the Ketamine Clinic at Oxford Health NHS Foundation Trust for their support of the research.

KH is an Emeritus National Institute for Health Research Senior Investigator.

Contributors

LM and KH designed the study. KL collected the data. KL and FB transcribed and analysed the data. KL and KH wrote the first draft of the report. All authors revised the report and approved the final version.

Funding

This work was supported by the Jim Pullin Trust.

RM is supported the NIHR Oxford Health Biomedical Research Centre and Collaborations for Leadership in Applied Health Research and Care.

Competing Interests


RM has received consulting fees from Janssen. Otherwise none declared.

Ethics Approval

Local Ethics Committee and Health Research Authority

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Figure 1: Participants' perspectives of mechanisms associated with reduced suicidal ideation (N=12)



Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist

Developed from:

Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *International Journal for Quality in Health Care*. 2007. Volume 19, Number 6: pp. 349 – 357

No. Item	Guide questions/description	Reported on Page #
Domain 1: Research team and reflexivity		
<i>Personal Characteristics</i>		
1. Interviewer/facilitator	Which author/s conducted the interview or focus group?	See Manuscript p6
2. Credentials	What were the researcher's credentials?	MSc
3. Occupation	What was their occupation at the time of the study?	Mental Health Nurse
4. Gender	Was the researcher male or female?	Female
5. Experience and training	What experience or training did the researcher have?	MSc Clinical Research; extensive clinical experience; interview techniques.
<i>Relationship with participants</i>		
6. Relationship established	Was a relationship established prior to study commencement?	No
7. Participant knowledge of the interviewer	What did the participants know about the researcher? e.g. personal goals, reasons for doing the research	Professional role – mental health nurse, researcher role in this study
8. Interviewer characteristics	What characteristics were reported about the interviewer/facilitator? e.g. Bias, assumptions, reasons and interests in the research topic	None reported. Researcher was also a mental health nurse.
Domain 2: study design		
<i>Theoretical framework</i>		
9. Methodological orientation and Theory	What methodological orientation was stated to underpin the study? e.g. grounded theory, discourse analysis, ethnography, phenomenology, content analysis	Descriptive, inductive phenomenological approach.
<i>Participant selection</i>		

10. Sampling	How were participants selected? e.g. purposive, convenience, consecutive, snowball	See manuscript p8; purposive sample
11. Method of approach	How were participants approached? e.g. face-to-face, telephone, mail, email	See manuscript p5
12. Sample size	How many participants were in the study?	See manuscript p8
13. Non-participation	How many people refused to participate or dropped out? Reasons?	See manuscript p8
<i>Setting</i>		
14. Setting of data collection	Where was the data collected? e.g. home, clinic, workplace	See manuscript p6
15. Presence of non-participants	Was anyone else present besides the participants and researchers?	No
16. Description of sample	What are the important characteristics of the sample? e.g. demographic data, date	See manuscript p8
<i>Data collection</i>		
17. Interview guide	Were questions, prompts, guides provided by the authors? Was it pilot tested?	Guide not attached. Guide was pilot tested.
18. Repeat interviews	Were repeat interviews carried out? If yes, how many?	No
19. Audio/visual recording	Did the research use audio or visual recording to collect the data?	See manuscript p6
20. Field notes	Were field notes made during and/or after the interview or focus group?	Yes
21. Duration	What was the duration of the interviews or focus group?	See manuscript p6
22. Data saturation	Was data saturation discussed?	No
23. Transcripts returned	Were transcripts returned to participants for comment and/or correction?	See manuscript p6
Domain 3: analysis and findings		
<i>Data analysis</i>		
24. Number of data coders	How many data coders coded the data?	See manuscript p7
25. Description of the coding tree	Did authors provide a description of the coding tree?	No
26. Derivation of themes	Were themes identified in advance or derived from the data?	Derived from data
27. Software	What software, if applicable, was used to manage the data?	NVIVO version 11
28. Participant checking	Did participants provide feedback on the findings?	No
<i>Reporting</i>		
29. Quotations presented	Were participant quotations presented to illustrate the themes/findings? Was each	Yes

	quotation identified? e.g. participant number	
30. Data and findings consistent	Was there consistency between the data presented and the findings?	Yes
31. Clarity of major themes	Were major themes clearly presented in the findings?	See manuscript: Table 4 p16
32. Clarity of minor themes	Is there a description of diverse cases or discussion of minor themes?	See manuscript

For peer review only

BMJ Open

Effects of ketamine treatment on suicidal ideation: a qualitative study of patients' accounts following treatment for depression in a UK ketamine clinic

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029108.R1
Article Type:	Research
Date Submitted by the Author:	11-Jun-2019
Complete List of Authors:	Lascelles, Karen; Oxford Health NHS Foundation Trust; Centre for Suicide Research, Department of Psychiatry, University of Oxford Marzano, Lisa; Middlesex University, Psychology Brand, Fiona; Centre for Suicide Research, University Department of Psychiatry, Oxford; Oxford Health NHS Foundation Trust Trueman, Hayley; Oxford Health NHS Foundation Trust McShane, Rupert; University of Oxford, Cochrane Dementia and Cognitive Improvement Group (CDCIG), Nuffield Department Medicine; Oxford Health NHS Foundation Trust Hawton, Keith; Centre for Suicide Research, Oxford University, Psychiatry
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Qualitative research
Keywords:	ketamine, treatment-resistant depression, mechanisms, self-harm, suicidal ideation

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9 **Effects of ketamine treatment on suicidal ideation: a qualitative study of patients'**
10 **accounts following treatment for depression in a UK ketamine clinic**
11
12
13
14

15
16 Karen Lascelles, Lisa Marzano, Fiona Brand, Hayley Trueman, Rupert McShane,
17
18 Keith Hawton
19
20
21
22

23 Corresponding Author:
24
25

26 Keith Hawton keith.hawton@psych.ox.ac.uk
27 Professor Keith Hawton, FMedSci DSc FRCPsych,
28 Director, Centre for Suicide Research,
29 University Department of Psychiatry,
30 and Consultant Psychiatrist,
31 Oxford Health NHS Foundation Trust,
32 Warneford Hospital,
33 Oxford, OX3 7JX. UK
34 Tel: 00 44 (0)1865 902285
35
36
37
38

39 Author:
40

41 Karen Lascelles, Oxford Health NHS Foundation Trust; Centre for Suicide Research,
42 Department of Psychiatry, University of Oxford, Oxford UK
43
44

45 Co-authors:
46

47 Dr Lisa Marzano, Middlesex University, London UK
48 Fiona Brand, Oxford Health NHS Foundation Trust; Centre for Suicide Research, Department
49 of Psychiatry, University of Oxford, Oxford UK
50 Hayley Trueman, Oxford health NHS Foundation Trust, Oxford UK
51 Dr Rupert McShane, Oxford health NHS Foundation Trust, Oxford UK
52 Professor Keith Hawton, Oxford health NHS Foundation Trust; Centre for Suicide Research,
53 Department of Psychiatry, University of Oxford, Oxford UK
54

55 **Key words**
56

57 Ketamine, suicidal ideation, treatment-resistant depression, mechanisms, self-harm
58

59 Word count: 4900
60

ABSTRACT

Objective: It is recognised that ketamine treatment can reduce suicidal ideation (SI) in people with depression, at least in the short-term. However, information is lacking on patients' perspectives on such effects. Studying these can contribute to greater understanding of the mechanisms underlying impact of ketamine treatment on suicidal ideation. The aim of this study was to investigate patients' reports of the impact of treatment on their SI, the duration of effects and possible mechanisms.

Design and setting: This qualitative study consisted of semi-structured interviews with patients who had received ketamine treatment for depression. Interview data were analysed thematically.

Participants: Fourteen patients (8 females, 6 males, aged 24-64 years) who received treatment with ketamine for treatment-resistant depression, and had SI at the initiation of treatment. Two participants also had a diagnosis of bipolar type 1 and two of emotionally unstable personality disorder. Eight had a history of self-harm.

Results: SI reduced following ketamine treatment in 12 out of 14 participants for periods of a few hours following a single treatment to up to three years with ongoing treatment. Reduction of SI was variable in terms of extent and duration, and re-emergence of suicidal thoughts often occurred when treatment ceased. Participants' accounts indicated that reduced SI was associated with improved mood and reduced anxiety, as were clarity of thought, focus and concentration, and ability to function. Participants reported experiencing some or all of these effects in various orders of occurrence.

Conclusion: Generally, ketamine treatment was experienced as effective in reducing suicidal ideation, although duration of effects varied considerably. Patients' perspectives indicated similarities in the mechanisms of reduction in suicidal ideation, but some differences in their manifestation, particularly in relation to chronology. Experiences of this cohort suggest that reduced anxiety and improvement in ability to think and function were important mechanisms alongside, or in some cases independently of, improvement in mood. Further studies of patients' experiences are required to gain enhanced understanding of the variability of effects of ketamine on suicidal ideation and functionality.

Strengths and limitations of this study

- This is one of the first studies of the impact of ketamine on suicidal ideation based on qualitative investigation of patients' experiences.
- Participants comprised a heterogeneous group in terms of gender, age, and number and routes of treatments with ketamine.
- The study is limited by the relatively small number of participants.
- Suicidal ideation was identified through a single item on a depression scale.
- Some patients declined participation.

INTRODUCTION

1
2
3
4
5
6 Suicide is a major public health problem globally (1). It often occurs in the context of
7
8 depression (2,3). While both pharmacological and psychological treatments can reduce
9
10 depression and suicidality (4), there is an important group of individuals who have
11
12 treatment-resistant depression in whom suicidal thinking is common and who have
13
14 increased risk of a suicidal act (5). Ketamine has received increasing attention as a rapid-
15
16 acting antidepressant, with studies suggesting that a single low dose infusion has a
17
18 beneficial although transitory effect for patients with depression, including treatment-
19
20 resistant unipolar and bipolar depression (6–8). Multiple mechanisms have been described
21
22 for the antidepressant action of ketamine: NMDA antagonism, reduced inhibitory
23
24 interneuron GABAergic transmission, a glutamate surge, an AMPA mediated increase in
25
26 BDNF release, and mTOR dependent neuroplasticity (9). In terms of beneficial effects of
27
28 ketamine on suicidality there are several potential pathways, but the effects on the
29
30 glutaminergic system may predominate (10).
31
32
33
34
35
36
37
38
39

40 There is accumulating evidence from clinical and randomised controlled trials that ketamine
41
42 can reduce suicidal ideation (SI), at least in the short term (11–13). However, there is
43
44 uncertainty as to the mechanisms which might underlie this effect (14). Reduction in SI
45
46 mediated by improvement in overall depressive symptoms may be one factor (15), but it
47
48 also seems that improvements can occur independently from changes in mood (16–18).
49
50 As far as we are aware, research to date has not examined patient views regarding the
51
52 impact of ketamine treatment on SI or sought to understand how patients think that
53
54 ketamine has reduced their SI. The aim of this qualitative study was to explore patient
55
56
57
58
59
60

1
2
3 perspectives on the impact of ketamine treatment on SI in the context of treatment-
4
5 resistant depression, including perceived benefits and how these might occur.
6
7
8
9

10 **METHOD**

11 **Participants**

12
13 Inclusion criteria consisted of a diagnosis of unipolar or bipolar treatment resistant
14
15 depression, age 18 years or over, English speaking and SI at commencement of ketamine
16
17 treatment. All participants had received ketamine treatment within the past year apart
18
19 from one who had last received it 22 months prior to interview. SI was assessed by a score
20
21 of 1 or above on the suicidal ideation question of the Beck Depression Inventory (BDI) (19).
22
23 Exclusion criteria were a lack of mental capacity, significant impairment of intellectual
24
25 functioning and lack of fluency in spoken English. Participants were in receipt of a range of
26
27 other antidepressant, anxiolytic, mood stabiliser and psychological treatments, which were
28
29 not prescribed by the ketamine clinic.
30
31
32
33
34
35
36
37
38
39

40 **Recruitment**

41
42 All participants were recruited from a UK ketamine clinic. Standard treatment at this clinic is
43
44 an initial three intravenous ketamine treatments (infusions) [0.5mg/kg] followed by oral
45
46 ketamine or a combination of oral and intravenous treatments as needed.
47
48
49
50

51
52 Forty eligible participants were approached by the ketamine clinic staff (HT and RM) by
53
54 email or in person at the clinic. Participant information sheets were provided and
55
56 interested individuals were referred to the researcher (KL), who then provided further
57
58 information before undergoing the informed consent process (see online appendix for
59
60

1
2
3 further information in the completed Consolidated Criteria for Reporting Qualitative
4 Research Checklist). Patients approached included both those who had responded
5
6 positively to ketamine treatment and patients who had not experienced any tangible
7
8 benefit or who had stopped treatment due to side-effects.
9
10
11
12
13
14

15 **Data collection**

16
17 Data collection was through one-to-one semi-structured interviews carried out by the
18 researcher (KL) at the hospital site where the ketamine clinic is based. All interviews were
19
20 carried out face-to face, although two longer interviews were carried out in two parts, with
21
22 the second parts by phone or skype. Topics included history of depression and suicidality,
23
24 the circumstances under which participants started ketamine treatment, their experiences
25
26 of treatment and perspectives on impact of ketamine on mood and SI. In addition,
27
28 participants were asked to complete the BDI before the interview commenced (only the
29
30 pre-treatment score was used to determine eligibility). They also completed benefits and
31
32 side-effects checklists during the interview to gather structured information about
33
34 frequency and duration of effects.
35
36
37
38
39
40
41
42
43
44

45 The length of interviews ranged from one to two and a half hours. All interviews were tape
46
47 recorded. Participants were advised that they could withdraw from the study at any time
48
49 and provided with information about sources of support in case they became distressed
50
51 following the interview.
52
53
54
55
56
57
58
59
60

Analysis

Interview data were transcribed verbatim and participants were given the opportunity to review their anonymised transcripts. Six participants took up this opportunity but none suggested changes. Thematic analysis was carried out to report participants' experiences, meanings and realities using an inductive and semantic approach, following the six stages of analysis recommended by Braun and Clarke (2006) (20): 1. Becoming familiar with the data; 2. Generating initial codes; 3. Searching for themes; 4. Reviewing themes; 5. Defining and naming themes; 6. Write-up. Final identification of themes was based on consensus discussion between two researchers (KL and FB), and was supported by NVIVO software (version 11 QSR 2008). Main themes and subthemes were first identified in relation to separate participants, and then across the whole sample. The qualitative analysis was supervised by LM.

Patient and public involvement

A former patient of the ketamine clinic was involved in reviewing and providing feedback on the interview schedule and participant information literature prior to submission to the Local Research Ethics Committee.

Ethical approval

The study was approved by the South Central Oxford A Research Ethics Committee and the Health Research Authority (Reference No. 17/SC/0106).

RESULTS

Participants

In total, 40 current and past patients were approached (21 females and 19 males). 18 individuals expressed initial interest in the study and 14 (35%, 8 females and 6 males) went on to participate. Of the 4/18 patients who did not go on to take part, three didn't respond to invitations to meet with the researcher and one withdrew before the informed consent process. One of the final 14 participants had stopped treatment 16 months prior to commencement of the study (22 months prior to interview) due to non-response but was included in the sample to ensure a range of perspectives. Participants were predominantly White British (13/14), with one classed as White Other. Ages ranged from 24-64 years, with a median age of 41 years. Most (11) participants lived with others (spouses, partners, parents, house share, student accommodation), with three living alone. Six participants were registered as sick or disabled at the time of their interviews.

All 14 participants met criteria for treatment-resistant depression (5). Two had a primary diagnosis of bipolar affective disorder type 1, two a diagnosis of emotionally unstable personality disorder, and the remaining 10 a primary diagnosis of depression. BDI scores for the suicidal ideation question at the start of ketamine treatment and at interview are shown in Table 1.

(Table 1 about here)

Ketamine treatment

Ten participants were engaged in ongoing ketamine treatment at the time of interview. Of the remaining four, one had received ketamine a month prior to interview, two nine months

1
2
3 before and one 22 months prior to interview. Reasons for cessation of treatment were non-
4 response (N=1), treatment becoming ineffective over time (N=1), severe side-effects (N=1),
5
6 and a lack of supply of oral ketamine (N=1).
7
8
9

10
11
12
13 There was considerable variation in the length of time participants were involved in
14
15 treatment. Two individuals received between one and three infusions over a few weeks, five
16
17 had between 6 and 88 infusions and up to 199 oral doses over a year or more (19 months –
18
19 6 years, three consistently and two periodically). The length of treatment and number of
20
21 doses for the remaining seven was somewhere between these points (3-6 infusions and up
22
23 to 46 oral doses over 4-9 months).
24
25
26
27
28
29

30 **Impact of ketamine on suicidal ideation**

31
32 Twelve participants reported a reduction in SI at some stage following ketamine treatment.
33
34 This group included the two participants with bipolar disorder and one of the individuals
35
36 with emotionally unstable disorder. The onset and duration of this effect varied; onset
37
38 ranged from immediate to a day or more after treatment, and duration from less than 24
39
40 hours to three years with ongoing treatment (Table 2). One patient who reported a
41
42 reduction in suicidal ideation had treatment stopped after one infusion due to adverse side-
43
44 effects (see below). Of the two participants who did not report a reduction in SI, one did
45
46 not experience any noticeable benefit from ketamine at all apart from a mild and transient
47
48 improvement in mood; the other experienced improved energy levels and cognitive
49
50 function but only rarely any improvement in mood.
51
52
53
54
55
56
57
58
59
60

1
2
3 Four participants experienced sustained elimination of suicidal ideation on both intravenous
4
5 and oral ketamine.
6
7

8 *“And the strongest thing that’s come out of the ketamine is that it doesn’t*
9
10 *matter how down I’ve got, after maybe the first one, maybe two, the idea of*
11
12 *suicide is not there” (P3).*
13
14

15 (Table 2 about here)
16
17

18
19
20 Two of these four participants (three of whom were receiving ketamine at the time of
21
22 interview) noticed a return of SI during periods they were without treatment (between
23
24 intravenous and oral treatment, or when they ran out of oral treatment), although stated
25
26 that the ideation was less intense.
27
28

29
30 *“[SI returned] Only when I’ve been off it for two months.... but not quite as bad as*
31
32 *I’ve experienced it before..... the fact that the thought had flashed into my mind*
33
34 *at all was like, ah and now it’s time to get in contact.” (P6)*
35
36
37
38
39

40 Three participants experienced an elimination of SI following intravenous treatment, which
41
42 lasted from 6 hours to 9 months (6 hours; 6-8 days; 3-9 months). One of these participants
43
44 had only ever received intravenous ketamine; the others had received both intravenous and
45
46 oral treatment but experienced elimination of SI only with intravenous administration,
47
48 although they reported a reduced intensity of suicidal ideation on oral ketamine.
49
50

51
52 *“I thought if it doesn’t work, on the way back, because we were staying in a hotel*
53
54 *on the way back, and I was going to kill myself there.....I actually went and*
55
56 *had dinner with my dad in the hotel room on the way back, which I’ve never done*
57
58 *before. Usually I wouldn’t be up to doing that mood wise. And I was able to eat*
59
60

1
2
3 *and enjoy the food..... [The oral] never had the impact of reducing the suicidal*
4
5 *thoughts to the extent that the infusion did..... on the infusion they*
6
7 *disappeared.” (P8)*
8
9

10
11
12
13 A further participant had only one full intravenous treatment before stopping due to side
14
15 effects (exacerbated hallucinations and intrusive unpleasant and paranoid thoughts), but
16
17 reported a period of a few hours of relief from persistent SI on the third day after the first
18
19 treatment, which they attributed to the ketamine.
20
21

22
23
24
25 A reduction in SI was reported by six participants (including two of the three discussed
26
27 above who experienced elimination of thoughts of suicide on intravenous ketamine but not
28
29 oral), which manifested as a reduction in intensity rather than frequency, with content
30
31 unchanged.
32
33

34
35 *“The intensity of the thought is definitely reduced.....I can cope with the*
36
37 *frequency, lots of them at a small level, I’m so used to them that it doesn’t bother*
38
39 *me. But if I get lots at a high intensity, this is when things start to break down.*
40
41 *So reducing the intensity is the first step for me.” (P2)*
42
43
44
45
46

47 The intravenous ketamine treatment was experienced as considerably stronger and, for
48
49 most participants, more effective than oral treatment in reducing SI, although eight of the
50
51 nine individuals who had oral treatment did report some benefit from it.
52
53

54 *“The oral dose, I suppose is stopping me from doing a suicide attempt even*
55
56 *though I still have those suicidal feelingsit lessened the intensity of them so*
57
58
59
60

1
2
3 *I would think I'll hold on for a bit longer and see what, thinking more of other*
4
5 *people.” (P8)*
6
7
8
9

10 Notwithstanding the greater effect of intravenous ketamine, one participant preferred the
11 regime of having the more regular, albeit lower, doses permitted by taking ketamine orally.
12
13 Another favoured oral treatment because, although it did not eradicate suicidal ideation as
14 the intravenous treatment did, there was not such a significant drop in mood when the
15 effects wore off and improved functionality was more sustained.
16
17
18
19
20
21
22
23
24

25 **Dissociative and euphoric effects**

26
27 Dissociative effects during ketamine treatment were experienced some or all of the time by
28 the 12 participants who reported a positive impact on SI (and also by the two participants
29 who did not experience reduced SI). For one participant, who went on to stop treatment
30 due to side effects, this was experienced as malevolent hallucinations and an acute increase
31 in pre-existing intrusive and disturbing thoughts and mental images. These effects
32 continued for two days post treatment and the participant reported a sustained worsening
33 of the pre-existing thoughts and images even at the point of interview. Dissociative effects
34 were more common and stronger with intravenous treatment and one participant reported
35 no dissociative effects at all with oral treatment. To describe the difference one participant
36 likened the oral ketamine to a drinking a glass of wine and the intravenous to consuming a
37 bottle of vodka.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

57 Participants were not asked specifically if they thought the reduction in their suicidal
58 ideation was linked to the dissociative effects they experienced. However, when asked if
59
60

1
2
3 they had discovered ways of maximising the overall benefit of ketamine, five participants
4
5 said they would take oral ketamine on an empty stomach to achieve a stronger sense of
6
7 dissociation and derive more benefit, suggesting they believed there was such a link,
8
9 although two participants noted that in practice this was not always the case.
10
11

12
13 *“Sometimes I won’t get as much of a kick from taking it, almost not notice
14
15 and I’m like did I get any? and then the next week will be fine. Sometimes I’d
16
17 get a really powerful thing and the next week felt down, so there was definitely
18
19 some stuff going on there that was beyond my ability to make sense of.” (P6)
20
21
22
23
24*

25 One participant reported getting the giggles and feeling like a ‘happy drunk’ during
26
27 intravenous ketamine treatment and two others described clear euphoric effects.
28
29

30 *“It was like a weight had been lifted off my shoulders. It was like I’d let go of a
31
32 big weight, like a heavy weight had shifted from me. It was absolutely amazing.”
33
34*

35 (P1)
36

37 These three participants all experienced an eradication of SI following ketamine infusions.
38
39 For two this was transitory and for one it was longer lasting (for some months following a
40
41 course of four infusions).
42
43
44
45
46

47 **Other Side-effects**

48

49 All participants experienced some side-effects, including the effects during ketamine
50
51 administration, ranging from rarely to always (the most frequently reported of which were
52
53 feeling strange or unreal (N=14), abnormal sensations such as seeing or hearing unusual
54
55 things (N=11), tiredness (N=11), blurred vision (N=8) and headaches (N=7)). One participant
56
57 reported severe side-effects resulting in cessation of treatment (see above). For the rest of
58
59
60

1
2
3 the participants (N=13), however, side-effects were not considered major and six explicitly
4
5 stated that the side-effects they experienced from ketamine were much less severe than
6
7 those they had experienced with conventional antidepressants. No participant described an
8
9 association between side-effects and impact of ketamine on suicidal ideation, nor did any
10
11 individual require prescribed medication to address side-effects.
12
13
14
15
16
17

18 **Perceived mechanisms contributing to reduced suicidal ideation**

19
20 Participants rated the frequency with which they experienced benefits following ketamine
21
22 treatment using a structured checklist (Table 3). Of the 12 participants whose SI was
23
24 reduced by ketamine, five reported that they always experienced a reduction in SI following
25
26 treatment, although improved mood, reduced anxiety and increased energy were
27
28 experienced less regularly. This suggests that in some cases SI was reduced independently
29
30 of mood and anxiety.
31
32
33
34

35 *"I think it's separate [from mood]. Because there's still days where I feel very low*
36
37 *and normally the suicide thing would be at the back of my head or be there, but*
38
39 *it, without any thought process, it's gone, and I can't reason that one."* (P3)
40
41
42
43
44

45 Table 3 about here
46
47
48
49

50 Themes derived from participants' narratives reflect the checklist findings and indicate that
51
52 whilst improved mood and reduced anxiety were both associated with a reduction in SI,
53
54 clarity of thought, improved focus and concentration, and improved ability to function were
55
56 additional factors involved the alleviation of SI (Figure 1; Table 4). These perceptions were
57
58 consistent across the sample, and accounts of individuals with diagnoses of bipolar disorder
59
60

1
2
3 or emotionally unstable personality disorder did not appear to differ significantly from those
4
5 of participants with a primary diagnosis of depression.
6
7
8
9

10 (Figure 1 about here)
11
12
13
14

15 Participants reported similar perceptions of the mechanisms involved in reduction of
16
17 suicidal ideation but some differences in experiences of order of occurrence. Most (N=8)
18
19 perceived that an improvement in mood resulted in reduced suicidal ideation, but for others
20
21 the improvement in mood was itself a result of improved clarity of thought and the
22
23 associated ability to focus.
24
25
26

27 *"I think it may be more ways, not necessarily my mood, maybe that I could have a*
28 *gap in thinking without the thoughts coming in. So I could distract and therefore*
29 *look at other things that could help my mood, which then I suppose reduces the*
30 *suicidality, because when the mood goes really low I can't concentrate on*
31 *anything or think about other things. So basically, the ketamine helps to give you*
32 *a different perspective at looking outwards and being interested in different*
33 *things so I'm not being wound in constant thoughts."* (P8)
34
35
36
37
38
39
40
41
42
43
44
45
46

47 Improved clarity of thought was experienced by some participants (N=7) as a reduction in
48
49 intrusive thoughts or depressive ruminations. Such thoughts were negative and frequently
50
51 suicidal in nature and described as *'constant thoughts'*, *'tornado of thoughts'*, *'rapid fire*
52 *thoughts'*, *'head swimming'* and *'ruminations'*.
53
54
55

56 *"The day after [ketamine treatment] I maybe have more clarity of thought. I*
57 *think instead of maybe being so locked into the pattern of kind of cyclical thinking*
58
59
60

1
2
3 *and rumination, I think it does maybe break that up a bit and maybe make you a*
4
5 *bit more open to possibilities” (P4)*
6
7
8
9

10 Other participants (N=3) described a process of making sense of thoughts and reaching new
11 understandings or gaining new perspectives. Two of these participants used the same
12 metaphor (*“it’s like rinsing my brain out”, “it’s like having your brain jet washed”*) to
13 describe this experience. The remaining two participants experienced a relief from slowed
14 thinking and used the same descriptors for their state before treatment with ketamine
15 (*“nothingness”, “this blank nothing”*) and the metaphor of *“the fog lifting”* to describe how
16 they felt ketamine enabled clarity of thought.
17
18
19
20
21
22
23
24
25
26
27
28
29

30 Ketamine’s positive effect on anxiety was noticed by most participants who experienced a
31 reduction in suicidal ideation (N=11/12). Some put this down to the reduction in intrusive
32 negative and suicidal thoughts whereas others described a general reduction in anxiety that
33 was associated with improved ability to focus, which in turn prevented intrusive thoughts.
34
35
36
37
38
39

40 *“It’s linked with the focus right, so if you’re focused on your task or what’s in*
41 *front of you at the time, there’s no place for neurotic and other thoughts to kick*
42 *in and actually then lead you to suicidal thoughts” (P12)*
43
44
45
46
47
48
49

50 Clarity of thought and the ability to focus along with increased energy levels were linked to
51 improved functionality in relation to activities of daily living and socialisation.
52
53

54 *“By the thoughts being slowed down you automatically gain more control because you can isolate*
55 *them.....everything seems more manageable at a slower pace..... the mood is able to go up and the*
56
57
58
59
60

1
2
3 *suicidal thinking comes down.... It means I can do things. I can get out of bed. I can take my kids to*
4 *school. I can have a shower.....” (P2)*
5
6
7
8
9

10 (Table 4 about here)
11
12
13
14

15 Although participants were not specifically prompted about hopelessness, some accounts
16 suggested that this reduced somewhat as mood improved and the treatment was
17 experienced as being effective e.g.,
18
19

20 *“I think it’s because my mood improved and I had a reason to keep going. There wasn’t*
21 *this black hole that was always going to be there. And, you know, as soon as somebody*
22 *says ‘well you’re drug resistant to this’ you do, you go oh, bloody hell. So that’s it.” [p7]*
23
24
25
26
27
28
29
30
31

32 **Self-harm**

33
34 Two of the 14 study participants had self-harmed whilst undergoing ketamine treatment.

35
36 One of these reported an overall reduction in intensity of suicidal ideation. A third
37 participant, who had ketamine periodically over some years, had episodes of self-harm
38 when in a mental health crisis, while not receiving ketamine, which led to further courses of
39 ketamine treatment. A fourth participant had self-harmed since cessation of ketamine
40 treatment (due to side effects). All of these participants had a history of self-harm prior to
41 commencement of ketamine treatment.
42
43
44
45
46
47
48
49
50
51

52 **DISCUSSION**

53
54 In this study we explored patients’ accounts of the impact of ketamine treatment on their
55 suicidal thinking and perspectives of the associated mechanisms. Treatment with ketamine
56
57
58
59
60

1
2
3 was reported as reducing SI in 12 out of 14 participants. However, the intensity and duration
4 of effects on suicidal ideation varied greatly. In most clinical trials which have shown an
5 impact of a single treatment with ketamine on suicidal ideation, this effect has not usually
6 persisted beyond 72 hours (13,21,22), although has had longer effects in some patients. In
7 the present study, some participants who reported benefits in terms of reduced SI identified
8 a relatively long duration of effect. Grunebaum et al (2017) found an effect on suicidal
9 ideation up to 6 weeks following a single infusion of ketamine (12). Also, in our study all but
10 one individual had received multiple ketamine treatments. Some of these reported that
11 beneficial effects on suicidal ideation persisted with continuation of treatment, but that this
12 effect was lost if treatment was discontinued.

13
14
15 Differences between individual experiences of impact of ketamine on suicidality have been
16 noted by other authors, such as Ballard et al (2018) who found that those least likely to have
17 reduced SI following ketamine were those with the most severe SI and a history of self-
18 injury (18). Of the eight participants in our study who scored 2 or above in the BDI suicidal
19 ideation question, six had a history of self-harm. Five of these reported a beneficial impact
20 on SI; one complete elimination, two elimination with ketamine infusion and reduction with
21 oral treatment, and two an overall reduction. These findings indicate that most participants
22 who had stronger SI and a history of self-harm experienced a reduction in SI following
23 ketamine treatment. The rest of the participants (N=6) had less severe SI and fewer (N=2)
24 had a history of self-harm. However, responses of this group were similar to the group with
25 higher SI; one reported no response; two reduced SI and three elimination of SI.

1
2
3 One possibility for optimising improvement in thought processes and functionality
4
5 experienced following ketamine treatment, and hence longer-term benefits for both
6
7 depression and suicidal ideation, could be additional use of intensive psychological therapy.
8
9

10 Some participants in this study spontaneously mentioned the need for psychological
11
12 treatment and the fact that ketamine made them feel more amenable to therapy or more
13
14 able to utilise skills learnt in previous therapy. Repeated treatment with ketamine, as was
15
16 the case for several participants in this study, is another approach.
17
18
19

20
21
22 Previous research has indicated that a single dose of ketamine has a short-term positive
23
24 effect on hopelessness as well as suicidal ideation (23,24). In our study some participants'
25
26 accounts suggested that reduced hopelessness was experienced alongside or subsequent to
27
28 improvement in mood and due to the relief of finding a treatment that was more effective
29
30 than those previously tried, however, hopelessness was not systematically explored in this
31
32 study.
33
34
35
36
37
38
39

40 **Potential mechanisms of impact of ketamine on SI**

41
42 Participants' accounts indicated that they regarded the beneficial effects of ketamine on SI
43
44 to be partly related to improvements in depression and anxiety. However, some also related
45
46 the impact on suicidal ideation to improved clarity of thinking and functionality. This is in
47
48 keeping with findings from other studies that improvements in SI following a single
49
50 treatment with ketamine can occur partly independently of improvements in mood, with
51
52 improvement in depression explaining about 50% of the improvement in suicidal ideation
53
54 (12,13). Grunebaum et al (2017) found that reduced SI largely continued up to six weeks
55
56 post infusion and explained that this is likely to be partly due to concomitant treatment with
57
58
59
60

1
2
3 other psychotropic medication, although the participants were not necessarily suffering
4
5 from treatment-resistant depression (12).
6
7
8
9

10 **Research implications**

11
12 The variety of responses found in this study and other investigations indicate that measures
13
14 of impact should be monitored frequently in trials assessing the impact of ketamine on
15
16 suicidal ideation and behaviour. Further work is needed to try to identify likely responders.
17
18 This will be particularly important should ketamine be used for management of SI in
19
20 emergency situations. Our findings, and those of others (12,18), suggest that there should
21
22 be more focus on investigating the mechanisms involved in beneficial effects of ketamine on
23
24 SI. We would encourage deployment of mixed-methods studies, including nested qualitative
25
26 studies within RCTs, for this purpose and for obtaining a more nuanced appraisal of the
27
28 effects of ketamine than may be possible by only using scales to assess impact.
29
30
31
32
33
34
35
36
37

38 **Strengths and limitations**

39
40 We are unaware of previous qualitative studies of the experiences of depressed patients
41
42 with suicidal ideas receiving treatment with ketamine. The approach we have used
43
44 encourages a real-world appraisal of the impact of ketamine and allows highlighting of
45
46 individual patients' experiences. However, there are limitations, especially in terms of the
47
48 small sample size and the potential lack of generalisability associated with the qualitative
49
50 methodology. In addition, participants who responded to invitations to participate were
51
52 self-selected and there may be some bias in terms of those agreeing to participate perhaps
53
54 having experienced a more positive impact on their SI than those who declined. The
55
56 inclusion criteria included a positive score on a single item on a mood scale, the Beck
57
58
59
60

1
2
3 Depression Scale. Differences in response to ketamine in terms of suicidal ideation have
4
5 been found when different measures of suicidal ideation have been used (13). The
6
7 participants all attended a single clinic, which may also influence the generalisability of the
8
9 findings. Furthermore, the interviews were conducted retrospectively and at varying times
10
11 following initiation of treatment, with some participants still receiving ketamine and others
12
13 having ceased treatment.
14
15
16
17
18
19

20 **Conclusions**

21
22 This study of patients' experiences of treatment with ketamine has indicated variable
23
24 responses in terms of changes in suicidal ideation, both in intensity and duration of benefits.
25
26 The patients' perceptions of mechanisms involved in a reduction of suicidal ideation suggest
27
28 that improvements in depression and anxiety are just part of the effect, with improved
29
30 clarity of thinking and functionality also being important. Further studies of patients'
31
32 experiences are warranted, especially in terms of understanding variability of effects of
33
34 ketamine on suicidality, including hopelessness and actual suicidal behaviour, and how
35
36 benefits of the medication might interact with activities of daily living and other treatments,
37
38 including possible psychological therapy. Such work should add to knowledge about the
39
40 suitability of use of ketamine to treat suicidality, especially in potential emergency
41
42 situations. In addition, whilst we cannot comment of the effect of ketamine on repeat self-
43
44 harm of people with emotionally unstable personality disorder, given that individuals with
45
46 this diagnosis are in receipt of ketamine treatment such study would be judicious.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. World Health Organization (WHO). Preventing suicide: A global imperative. World Health Organization. 2014.
2. Cavanagh JTO, Carson AJ, Sharpe M, Lawrie SM. Psychological autopsy studies of suicide: a systematic review. *Psychol Med*. 2003;33(3):395–405.
3. Brezo J, Paris J, Turecki G. Personality traits as correlates of suicidal ideation, suicide attempts, and suicide completions: a systematic review. *Acta Psychiatr Scand*. 2006;113:180–206.
4. Zalsman G, Hawton K, Wasserman D, van Heeringen K, Arensman E, Sarchiapone M, et al. Suicide prevention strategies revisited: 10-year systematic review. *The Lancet Psychiatry*. 2016;3(7):646–59.
5. Anderson IM. We all know what we mean by treatment-resistant depression – Don't we? *Br J Psychiatry*. 2018;212(5):259–61.
6. Caddy C, BH A, TL M, JM R, TA F, McShane R, et al. Ketamine and other glutamate receptor modulators for depression in adults. *Cochrane Database Syst Rev*. 2015;9:CD011612.
7. McCloud TL, Caddy C, Jochim J, Rendell JM, Diamond PR, Shuttleworth C, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. *Cochrane Database Syst Rev*. 2015;9:CD011611.
8. Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK. Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. *Aust N Z J Psychiatry*. 2013;47(8):710–27.

- 1
2
3 9. Abdallah CG, Sanacora G, Duman RS, Krystal JH. The neurobiology of depression,
4 ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?
5
6 Pharmacol Ther. 2018;190:148–58.
7
8
9
- 10
11 10. De Berardis D, Fornaro M, Valchera A, Cavuto M, Perna G, Di Nicola M, et al.
12
13 Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy
14
15 of Ketamine in the Treatment of Suicidal Behaviors. *Int J Mol Sci*. 2018;19:2888.
16
17
18
- 19
20 11. Bartoli F, Riboldi I, Crocamo C, Di Brita C, Clerici M, Carrà G. Ketamine as a rapid-
21
22 acting agent for suicidal ideation: A meta-analysis. *Neurosci Biobehav Rev*.
23
24 2017;77:232–6.
25
26
- 27
28 12. Grunebaum MF, Galfalvy HC, Choo TH, Keilp JG, Moitra VK, Parris MS, et al. Ketamine
29
30 for rapid reduction of suicidal thoughts in major depression: A midazolam-controlled
31
32 randomized clinical trial. *Am J Psychiatry*. 2017;175:327–33.
33
34
- 35
36 13. Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al. The
37
38 effect of a single dose of intravenous ketamine on suicidal ideation: A systematic
39
40 review and individual participant data meta-analysis. *Am J Psychiatry*.
41
42 2018;175(2):150–8.
43
44
- 45
46 14. Price RB, Mathew SJ. Does ketamine have anti-suicidal properties? Current status and
47
48 future directions. *CNS Drugs*. 2015;29(3):181–8.
49
50
- 51
52 15. Price RB, Iosifescu D V., Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, et al. Effects of
53
54 ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in
55
56 treatment-resistant depression. *Depress Anxiety*. 2014;31(4):335–43.
57
58
- 59
60 16. Phillips JL, Norris S, Talbot J, Owoeye O, Blier P. Direct effect of ketamine on suicidal

- 1
2
3 ideation independent of its effects on depressive symptoms. *Eur*
4
5
6 *Neuropsychopharmacol.* 2016;26:S472.
7
8
9 17. Ballard ED, Wills K, Lally N, Richards EM, Luckenbaugh DA, Walls T, et al. Anhedonia as
10
11 a clinical correlate of suicidal thoughts in clinical ketamine trials. *J Affect Disord.*
12
13 2017;218:195–200.
14
15
16 18. Ballard ED, Yarrington JS, Farmer CA, Richards E, Machado-Vieira R, Kadriu B, et al.
17
18 Characterizing the course of suicidal ideation response to ketamine. *J Affect Disord.*
19
20 2018;241:86–93.
21
22
23
24 19. Beck AT, Schuyler D, Herman I, Resnik HLP, Lettieri DJ. Development of Suicidal Intent
25
26 Scales. In: *The Prediction of Suicide*. Philadelphia, PA: Charles Press; 1974. p. 45–56.
27
28
29
30 20. Braun V, Clarke V. Using Thematic Analysis in Psychology. *Qual Res Psychol.*
31
32 2006;3:77–101.
33
34
35
36 21. Xu Y, Hackett M, Carter G, Loo C, Gálvez V, Glozier N, et al. Effects of Low-Dose and
37
38 Very Low-Dose Ketamine among Patients with Major Depression: A Systematic
39
40 Review and Meta-Analysis. *Int J Neuropsychopharmacol.* 2016;19(4):pyv124.
41
42
43
44 22. Murrough JW, Iosifescu D V., Chang LC, Al Jurdi RK, Green CE, Perez AM, et al.
45
46 Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-
47
48 site randomized controlled trial. *Am J Psychiatry.* 2013;170(10):1134–42.
49
50
51
52 23. DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, et al.
53
54 Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate
55
56 antagonist in patients with treatment-resistant major depressive disorder. *J Clin*
57
58 *Psychiatry.* 2010;71(12):1605–11.
59
60

- 1
2
3 24. Burger J, Capobianco M, Lovern R, Boche B, Ross E, Darracq MA, et al. A Double-
4 Blinded, Randomized, Placebo-Controlled Sub-Dissociative Dose Ketamine Pilot Study
5
6 in the Treatment of Acute Depression and Suicidality in a Military Emergency
7
8 Department Setting. Mil Med. 2016;181(10):1195–9.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1 Characteristics of the participants (N=14)

Characteristics	N=14
Gender (male/female)	6/8
Age (years)	24-64; median 41
Past self-harm	8
Family history of self-harm or suicide	4
BDI suicidal ideation score:	
At commencement of treatment	1 N=7
	2 N=5
	3 N=2
At interview	0 N=6
	1 N=4
	2 N=3
	3 N=1

Table 2: Impact of ketamine on suicidal ideation (SI) in those patients who experienced benefit (N=12)

Onset of reduced SI	N=12
Immediate/during treatment	2
Within an hour of treatment	5
A few hours after treatment	2
A day or more after treatment	3
Duration of reduced SI	
0-24 hours	2
Several days	4 (3-6 days)
A week or more	0
A month or more	1
Ongoing	5

Table 3: Participants' responses regarding specific impacts of ketamine

		Participants with reduced suicidal ideation (N=12)	Participants with no reduction in suicidal ideation (N=2)
Ketamine reduced suicidal ideation	Always	5*	
	Often	5	
	Sometimes	2	
	Never		2
Ketamine improved mood	Always	3*	1
	Often	7	
	Sometimes	2	1
Ketamine reduced anxiety	Always	2*	
	Often	8	1
	Sometimes	1	
	Rarely		1
	Never	1	
Ketamine increased energy levels	Always	2	
	Often	5	1
	Sometimes	5*	
	Rarely		1

*One of these participants had only 1 full intravenous treatment due to severe side-effects

Table 4: Key themes, subthemes and perceived impact of subthemes

Main Themes	Subthemes	Perceived Subthemes
1. Clarity of thought	Reduced intrusive thoughts Relief from slowed thoughts Reaching new understandings	Getting a break
2. Focus and concentration	Able to make decisions Motivation and energy	Choosing not to act on SI Able to let go Seeing other options
3. Ability to function	Activities of daily living Socialisation	Doing normal stuff Improved connection with others

Author Affiliations:

¹ Oxford Health NHS Foundation Trust

² Centre for Suicide Research, Department of Psychiatry, University of Oxford

³ Faculty of Science and Technology, Middlesex University

Acknowledgements

The authors thank Suzanne Pullin and Charlie Pullin for their funding, Chris Dammers for his contribution to the research design and the staff of the Ketamine Clinic at Oxford Health NHS Foundation Trust for their support of the research.

KH is an Emeritus National Institute for Health Research Senior Investigator.

Contributors

LM, KH and KL designed the study, with the assistance of HT and RM, who both helped recruit the participants. KL collected the data. KL and FB transcribed and analysed the data. KL and KH wrote the first draft of the report. All authors revised the report and approved the final version.

Funding

This work was supported by the Jim Pullin Trust.

RM is supported the NIHR Oxford Health Biomedical Research Centre and Collaborations for Leadership in Applied Health Research and Care.

Competing Interests

RM has received consulting fees from Janssen. Otherwise none declared.

Ethics Approval


Local Ethics Committee and Health Research Authority

Data Sharing Statement

Due to the qualitative nature of this study, full transcripts of the interviews cannot be made available as these could potentially identify study participants.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Figure 1: Participants' perspectives of mechanisms associated with reduced suicidal ideation (N=12)



Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist

Developed from:

Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *International Journal for Quality in Health Care*. 2007. Volume 19, Number 6: pp. 349 – 357

No. Item	Guide questions/description	Reported on Page #
Domain 1: Research team and reflexivity		
<i>Personal Characteristics</i>		
1. Interviewer/facilitator	Which author/s conducted the interview or focus group?	See Manuscript p6
2. Credentials	What were the researcher's credentials?	MSc
3. Occupation	What was their occupation at the time of the study?	Mental Health Nurse
4. Gender	Was the researcher male or female?	Female
5. Experience and training	What experience or training did the researcher have?	MSc Clinical Research; extensive clinical experience; interview techniques.
<i>Relationship with participants</i>		
6. Relationship established	Was a relationship established prior to study commencement?	No
7. Participant knowledge of the interviewer	What did the participants know about the researcher? e.g. personal goals, reasons for doing the research	Professional role – mental health nurse, researcher role in this study
8. Interviewer characteristics	What characteristics were reported about the interviewer/facilitator? e.g. Bias, assumptions, reasons and interests in the research topic	None reported. Researcher was also a mental health nurse.
Domain 2: study design		
<i>Theoretical framework</i>		
9. Methodological orientation and Theory	What methodological orientation was stated to underpin the study? e.g. grounded theory, discourse analysis, ethnography, phenomenology, content analysis	Descriptive, inductive phenomenological approach.
<i>Participant selection</i>		

10. Sampling	How were participants selected? e.g. purposive, convenience, consecutive, snowball	See manuscript p8; purposive sample
11. Method of approach	How were participants approached? e.g. face-to-face, telephone, mail, email	See manuscript p5
12. Sample size	How many participants were in the study?	See manuscript p8
13. Non-participation	How many people refused to participate or dropped out? Reasons?	See manuscript p8
<i>Setting</i>		
14. Setting of data collection	Where was the data collected? e.g. home, clinic, workplace	See manuscript p6
15. Presence of non-participants	Was anyone else present besides the participants and researchers?	No
16. Description of sample	What are the important characteristics of the sample? e.g. demographic data, date	See manuscript p8
<i>Data collection</i>		
17. Interview guide	Were questions, prompts, guides provided by the authors? Was it pilot tested?	Guide not attached. Guide was pilot tested.
18. Repeat interviews	Were repeat interviews carried out? If yes, how many?	No
19. Audio/visual recording	Did the research use audio or visual recording to collect the data?	See manuscript p6
20. Field notes	Were field notes made during and/or after the interview or focus group?	Yes
21. Duration	What was the duration of the interviews or focus group?	See manuscript p6
22. Data saturation	Was data saturation discussed?	No
23. Transcripts returned	Were transcripts returned to participants for comment and/or correction?	See manuscript p6
Domain 3: analysis and findings		
<i>Data analysis</i>		
24. Number of data coders	How many data coders coded the data?	See manuscript p7
25. Description of the coding tree	Did authors provide a description of the coding tree?	No
26. Derivation of themes	Were themes identified in advance or derived from the data?	Derived from data
27. Software	What software, if applicable, was used to manage the data?	NVIVO version 11
28. Participant checking	Did participants provide feedback on the findings?	No
<i>Reporting</i>		
29. Quotations presented	Were participant quotations presented to illustrate the themes/findings? Was each	Yes

	quotation identified? e.g. participant number	
30. Data and findings consistent	Was there consistency between the data presented and the findings?	Yes
31. Clarity of major themes	Were major themes clearly presented in the findings?	See manuscript: Table 4 p16
32. Clarity of minor themes	Is there a description of diverse cases or discussion of minor themes?	See manuscript

For peer review only